Related Experiment Videos
Diabetes care in Norwegian pharmacies: a descriptive study
Reidun L S Kjome1, Sverre Sandberg, Anne Gerd Granås
1Section for General Practice, Department of Public Health and Primary Health Care, University of Bergen/ Institute for Pharmacy Practice Research (APOFORSK), Kalfarveien 31, 5018 Bergen, Norway. reidun.kjome@isf.uib.no
Pharmacy World & Science : PWS
|September 25, 2007
Summary
Norwegian pharmacists offer various diabetes care services, with a strong desire to expand. However, awareness of the national diabetes declaration is low, highlighting a gap in implementation for services like lifestyle counseling.
Area of Science:
- Pharmaceutical Sciences
- Public Health
- Diabetes Management
Background:
- The Norwegian diabetes declaration outlines recommendations for pharmacy involvement in diabetes care.
- Understanding current pharmacy services and future aspirations is crucial for optimizing patient support.
Purpose of the Study:
- To assess Norwegian pharmacies' current engagement in diabetes care.
- To explore pharmacists' perspectives on future diabetes-related services.
- To evaluate the implementation status of the Norwegian diabetes declaration for pharmacies.
Main Methods:
- A web-based questionnaire was distributed to all 543 pharmacies in Norway.
- One pharmacist from each participating pharmacy completed the survey.
- The questionnaire covered the diabetes declaration, future service views, and demographics.
Main Results:
- 358 (66%) pharmacies responded; 37% had read the diabetes declaration.
- High compliance with glucose monitoring recommendations; lower implementation for medication reviews (24%) and diabetes screening (10%).
- Lifestyle counseling was the least implemented service, yet 81% of pharmacists desired service expansion, particularly in glucose monitoring.
Conclusions:
- Norwegian pharmacists are engaged in diverse diabetes services and express a strong willingness to enhance their role.
- There is a significant gap between pharmacists' desire to provide services and their awareness/implementation of national recommendations.
- Further research should identify the most impactful areas for pharmacy involvement in diabetes care.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...